Trial to Determine Optimal Phase II Dose of the Oral Dual CAIX Inhibitor/ Radiosensitizer

NCT02216669 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No financial agreement

Conditions

Solid Tumors
Head and Neck Neoplasms

Interventions

DRUG: DTP348

Sponsor

Maastricht Radiation Oncology